We have shown that YAP expression and transcriptional activity immediately increase following one cycle of standard high risk neuroblastoma therapy, topotecan and cyclophosphamide, when given to mice harboring established neuroblastoma PDXs [51]. The gene discussed is YAP1; the disease is neuroblastoma.